Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy chinese subjects

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages

  Yang, Li ^a   Li, Haiyan ^a   Li, Hongmei ^b   Bui, Anh ^b   Chang, Ming ^b   Liu, Xiaoni ^b   Kasichayanula, Sreeneeranj ^b   Griffen, Steven C ^b   LaCreta, Frank P ^b   Boulton, David W ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chinese; Dapagliflozin; Pharmacodynamics; Pharmacokinetics; SGLT2; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; BRONCHITIS; CHINA; CHINESE; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE URINE LEVEL; GLUCOSURIA; HALF LIFE TIME; HUMAN; LEUKOCYTE; MALE; MULTIPLE DRUG DOSE; NEUTROPHIL; OPEN STUDY; SIDE EFFECT; STEADY STATE; URINARY EXCRETION;

CHINESE; DAPAGLIFLOZIN; PHARMACODYNAMICS; PHARMACOKINETICS; SGLT2; TYPE 2 DIABETES MELLITUS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; GLUCOSIDES; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 84882925901     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.017     Document Type: Article

References (24)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
2. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China. Zhonghua Nei Ke Za Zhi 1981, 11:678-683. National Diabetes Research Group.
3. Yang W., Lu J., Weng J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
4. International Diabetes Federation. IDF Diabetes Atlas: Fifth Edition. 2011. Accessed September 11, 2012. http://www.idf.org/atlasmap/atlasmap.
5. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
6. Komoroski B., Vachharajani N., Boulton D., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526.
7. Komoroski B., Vachharajani N., Feng Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513-519.
8. Francis J., Zhang J., Farhi A., et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004, 19:2893-2895.
9. Oemar B.S., Byrd D.J., Brodehl J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 1987, 27:156-160.
10. Scholl-Burgi S., Santer R., Ehrich J.H. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004, 19:2394-2396.
11. Rohwedder K., Hruba V., Salsali S., et al. Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Has a Low Propensity To Cause Hypoglycemia in Patients with Type 2 Diabetes. Diabetes 2011, 60(Suppl 1):A286. Abstract.
12. Ferrannini E., Jimenez Ramos S., Salsali A., et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010, 33:2217-2224.
13. Bailey C.J., Gross J.L., Pieters A., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
14. Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011, 34:2015-2022.
15. Strojek K., Yoon K.H., Hruba V., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011, 13:928-938.
16. Rosenstock J., Vico M., Wei L., et al. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes. Diabetes 2011, 60(Suppl 1). A270. Abstract 986-P.
17. Wilding J.P., Woo V., Soler N.G., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012, 156:405-415.
18. Bolinder J., Ljunggren O., Kullberg J., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97:1020-1031.
19. Woo V., Langkilde A.M., Sugg J., et al. Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Circulation 2011, 124:A9520. Abstract.
20. Bristol-Myers Squibb. Forxiga (dapagliflozin) [product information]. Accessed March 8, 2013. http://www.forxiga.eu/Forxiga%20Summary%20of%20Product%20Characteristics_SmPC_.pdf.
21. Kasichayanula S., Liu X., Zhang W., et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2011, 13:770-773.
22. Obermeier M., Yao M., Khanna A., et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010, 38:405-414.
23. Kasichayanula S., Chang M., Hasegawa M., et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:357-365.
24. Wilding J.P., Norwood P., T'Joen C., et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.